U.S. patent application number 16/504941 was filed with the patent office on 2020-06-18 for compositions containing nucleosides and manganese and their uses.
This patent application is currently assigned to The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.. The applicant listed for this patent is The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc The Government of the USA as Represented by the Se. Invention is credited to Michael J. Daly, Elena K. Gaidamakova, Rodney L. Levine, Vera Y. Matrosova, Nancy B. Wehr.
Application Number | 20200188515 16/504941 |
Document ID | / |
Family ID | 40526904 |
Filed Date | 2020-06-18 |
United States Patent
Application |
20200188515 |
Kind Code |
A1 |
Daly; Michael J. ; et
al. |
June 18, 2020 |
Compositions Containing Nucleosides and Manganese and Their
Uses
Abstract
This invention encompasses methods of preserving protein
function by contacting a protein with a composition comprising one
or more purine or pyrimidine nucleosides (such as e.g., adenosine
or uridine) and an antioxidant (such as e.g., manganese). In
addition, the invention encompasses methods of treating and/or
preventing a side effect of radiation exposure and methods of
preventing a side effect of radiotherapy comprising administration
of a pharmaceutically effective amount of a composition comprising
one or more purine or pyrimidine nucleosides (such as e.g.,
adenosine or uridine) and an antioxidant (such as e.g., manganese)
to a subject in need thereof. The compositions may comprise D.
radiodurans extracts.
Inventors: |
Daly; Michael J.;
(Washington, DC) ; Gaidamakova; Elena K.;
(Gaithersburg, MD) ; Matrosova; Vera Y.;
(Rockville, MD) ; Levine; Rodney L.; (Rockville,
MD) ; Wehr; Nancy B.; (Bethesda, MD) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
The Henry M. Jackson Foundation for the Advancement of Military
Medicine, Inc
The Government of the USA as Represented by the Secretary
Department of Health and Human Services |
Bethesda
Rockville |
MD
MD |
US
US |
|
|
Assignee: |
The Henry M. Jackson Foundation for
the Advancement of Military Medicine, Inc.
Bethesda
MD
The Government of the USA as Represented by the Secretary
Department of Health and Human Services
Rockville
MD
|
Family ID: |
40526904 |
Appl. No.: |
16/504941 |
Filed: |
July 8, 2019 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
14920765 |
Oct 22, 2015 |
10342871 |
|
|
16504941 |
|
|
|
|
12673709 |
Apr 15, 2011 |
9186406 |
|
|
PCT/US2008/073479 |
Aug 18, 2008 |
|
|
|
14920765 |
|
|
|
|
60935494 |
Aug 16, 2007 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61P 7/00 20180101; A61Q
17/04 20130101; A61P 1/00 20180101; A61K 31/7072 20130101; A61P
7/06 20180101; A61P 3/00 20180101; A61P 15/00 20180101; A61K 45/06
20130101; A61P 17/00 20180101; A61K 31/7076 20130101; A61K 8/99
20130101; A61K 8/44 20130101; A61P 43/00 20180101; A61K 35/74
20130101; A61K 8/606 20130101; A61P 17/14 20180101; A61K 33/32
20130101; A61P 39/06 20180101; A61K 8/24 20130101; A61P 39/00
20180101; A61K 31/7076 20130101; A61K 2300/00 20130101; A61K 33/32
20130101; A61K 2300/00 20130101 |
International
Class: |
A61K 45/06 20060101
A61K045/06; A61K 31/7072 20060101 A61K031/7072; A61K 31/7076
20060101 A61K031/7076; A61K 33/32 20060101 A61K033/32; A61K 35/74
20060101 A61K035/74; A61K 8/24 20060101 A61K008/24; A61K 8/44
20060101 A61K008/44; A61K 8/60 20060101 A61K008/60; A61Q 17/04
20060101 A61Q017/04; A61K 8/99 20060101 A61K008/99 |
Goverment Interests
GOVERNMENT SUPPORT
[0001] The present invention arose in part from research funded by
grant DE-FG02-04ER63918 from the U.S. Department of Energy, Office
of Science, Office of Biological and Environmental Remediation
Research (BER), Environmental Remediation Sciences Program and by
grant FA9559-07-1-0128 from the Air Force Office of Scientific
Research. The Government has certain rights in the invention.
Claims
1. A method of treating and/or preventing a side effect of
radiation exposure in a subject in need thereof comprising
administration of a pharmaceutically effective amount of a
composition comprising one or more purine nucleosides and one or
more antioxidants to a subject in need thereof.
2. The method of claim 1, wherein the radiation is selected from
the group consisting of UV light, alpha radiation, beta radiation,
gamma radiation, X-ray radiation and neutron radiation.
3. The method of claim 1, wherein the one or more purine
nucleosides is selected from the group consisting of adenosine,
uridine, .beta.-pseudouridine, inosine, and mixtures thereof.
4. The method of claim 1, wherein the one or more antioxidants is
selected from the group consisting of manganese, MnCl.sub.2, and
manganous phosphate.
5. The method of claim 1, wherein the composition further comprises
an amino acid selected from the group consisting of alanine, valine
and leucine.
6. The method of claim 1, wherein the composition comprises a D.
radiodurans extract.
7. The method of claim 1, wherein the method prevents one or more
side effects of radiotherapy.
8. The method of claim 1, wherein the concentration of one or more
purine nucleosides comprises about 1 to about 15 mM of adenosine
and/or uridine.
9. The method of claim 1, wherein concentration of the one or more
antioxidants comprises about 1 to about 12.5 mM of manganese.
10. A method for storing a protein comprising contacting a protein
with a composition comprising one or more purine nucleosides and
one or more antioxidants.
11. A method of treating and/or preventing a side effect of
radiation exposure in a subject in need thereof comprising
administration of a pharmaceutically effective amount of a D.
radiodurans extract comprising one or more purine nucleosides and
one or more antioxidants to a subject in need thereof.
12. The method of claim 11, wherein the radiation is selected from
the group consisting of UV light, alpha radiation, beta radiation,
gamma radiation, X-ray radiation and neutron radiation.
13. The method of claim 11, wherein the one or more purine
nucleosides is selected from the group consisting of adenosine,
uridine, .beta.-pseudouridine, inosine, and mixtures thereof.
14. The method of claim 11, wherein the one or more antioxidants is
selected from the group consisting of manganese, MnCl.sub.2 and
manganous phosphate.
15. The method of claim 11, wherein the D. radiodurans extract
further comprises an amino acid selected from the group consisting
of alanine, valine, and leucine.
16. The method of claim 11, wherein the method prevents one or more
side effects of radiotherapy.
17. The method of claim 11, wherein the concentration of one or
more purine nucleosides comprises about 1 to about 15 mM of
adenosine and/or uridine.
18. The method of claim 11, wherein concentration of the one or
more antioxidants comprises about 1 to about 12.5 mM of
manganese.
19. The method of claim 11, wherein the D. radiodurans extract
produced by a method comprising the steps of: harvesting a D.
radiodurans culture by centrifugation; lysing the D. radiodurans
culture to create a D. radiodurans lysate; washing the D.
radiodurans lysate; centrifuging the D. radiodurans lysate for a
time and under conditions sufficient to create a supernatant;
passing the supernatant through a less than 3 kiloDalton filter;
and boiling the supernatant for about 15 to about 45 minutes,
wherein the extract is soluble in butanol, resistant to boiling,
and cell-free.
Description
BACKGROUND OF THE INVENTION
[0002] The extremely radiation-resistant family Deinococcaceae is
comprised of greater than twenty distinct species that can survive
acute exposures to ionizing radiation (IR) (10 kGy), ultraviolet
light (UV) (1 kJ/m.sup.2), and desiccation (years); and can grow
under chronic IR (60 Gy/hour). In particular, Deinococcus
radiodurans is an extremely ionizing radiation (IR) resistant
bacterium that can survive exposures to gamma-radiation that exceed
by a factor of one thousand the doses which are cytotoxic and
lethal to mammalian cells
[0003] For extremely resistant bacteria, such as e.g., D.
radiodurans, survival following high-doses of IR has been
attributed to protection of proteins from oxidation during
irradiation, with the result that enzymic repair systems survive
and function with far greater efficiency during recovery than in
sensitive bacteria, where cellular proteins are highly susceptible
to carbonylation. In a report published in Science magazine (Daly
et al. (2004), Accumulation of Mn(II) in Deinococcus radiodurans
facilitates gamma-radiation resistance, Science 306: 925-1084),
intracellular manganese(II) was implicated in facilitating
radiation resistance by protecting proteins, but not DNA, during
exposure to ionizing radiation; and in a second report published in
PLoS Biology (Daly et al. (2007) Protein oxidation implicated as
the primary determinant of bacterial radioresistance, PLoS Biology
5(4) e92), radiation resistance was positively correlated to
protein protection during irradiation, mediated by a non-enzymic
mechanism.
[0004] Unlike D. radiodurans, most proteins are not
radiation-resistant. Similarly, most cells, whether in eukaryotes,
prokaryotes or mammals (e.g. humans) are also not radiation
resistant. As such, exposure to radiation is quite damaging to
protein structure and/or function. For example, ionizing radiation
has been shown to induce (cause) cancer in many different species
of animals and in almost all parts of the human body.
[0005] In humans, significant overexposure to radiation can result
in radiation poisoning, also called "radiation sickness" or a
"creeping dose". The term is generally used to refer to acute
problems caused by a large dosage of radiation in a short period,
though this also has occurred with long term exposure to low level
radiation. The clinical name for "radiation sickness" is acute
radiation syndrome as described by the CDC. A chronic radiation
syndrome does exist but is very uncommon; this has been observed
among workers in early radium source production sites and in the
early days of the Soviet nuclear program. A short exposure can
result in acute radiation syndrome; chronic radiation syndrome
requires a prolonged high level of exposure.
[0006] Humans routinely encounter radiation in daily life,
including radiation from electronic equipment and cell phones as
well as natural background radiation. Individuals that are in close
proximity of radioactive elements such as e.g. employees at a
nuclear plant or members of the armed forces are particularly
likely to encounter higher doses of radiation. Additionally,
radiation is used in diagnostic tests such as X-rays and radiation
therapy to treat cancers.
[0007] There are currently very few radioprotectors suitable for
treating humans, and those which exist (e.g., amifostine) are
cytotoxic and have serious side effects (e.g., loss of
consciousness, fast or irregular breathing, itching, nausea and
vomiting).
[0008] Given the great exposure to radiation, there is a
significant need for radioprotectors that are non-toxic, preserve
protein function, and in particular are suitable for human use.
SUMMARY OF THE INVENTION
[0009] This invention provides for methods of radioprotection using
compositions containing one or more purine nucleosides and one or
more antioxidant. These methods are suitable to protect proteins in
vitro and in vivo from the damaging effects of radiation.
[0010] One embodiment of the invention is a method of treating
and/or preventing a side effect of radiation exposure in a subject
in need thereof comprising administration of a pharmaceutically
effective amount of a composition comprising one or more purine or
pyrimidine nucleosides and one or more antioxidants to a subject in
need thereof. The method is suitable for treating and/or preventing
a side effect of exposure to many kinds of radiation. In one
embodiment, radiation is selected from the group consisting of UV
light, alpha radiation, beta radiation, gamma radiation, X-ray
radiation and neutron radiation. The purine or pyrimidine
nucleoside may be adenosine, uridine, .beta.-pseudouridine,
inosine, and mixtures thereof. The antioxidant may be manganese,
MnCl.sub.2, manganous phosphate and Vitamin E and/or mixtures
thereof. In one embodiment of the invention, the antioxidant is
manganous phosphate. In another embodiment, the antioxidant is
MnCl.sub.2 with phosphate added separately. In an alternate
embodiment, the composition further comprises an amino acid,
preferably any one of alanine, valine, and/or leucine. The
composition may be a D. radiodurans extract. In another embodiment,
the composition prevents one or more side effects of radiotherapy.
The composition may contain about 1 mM to about 15 mM of adenosine
and/or uridine. The composition may also contain about 1 mM to
about 12.5 mM of manganese.
[0011] Another embodiment of the invention is a method for
preserving a function of a protein comprising contacting a protein
with a composition comprising one or more purine or pyrimidine
nucleosides and one or more antioxidants. The one or more purine or
pyrimidine nucleoside may be adenosine, uridine,
.beta.-pseudouridine, inosine, and mixtures thereof. In one
embodiment, purine and/or pyrimidine nucleoside is adenosine and/or
uridine. In another embodiment, the composition contains about 1 to
about 15 mM of adenosine and/or uridine. The antioxidant may be
manganese, MnCl.sub.2, manganous phosphate and vitamin E. In one
embodiment of the invention, the antioxidant is manganous
phosphate. In another embodiment, the antioxidant is MnCl.sub.2
with phosphate added separately. In one embodiment, the composition
contains about 0.01 mM to about 12.5 mM of the antioxidant (such as
e.g., manganese). In another embodiment, the composition contains
adenosine, uridine, leucine, adenine, and manganese. In yet another
embodiment, composition contains about 1 to about 15 mM adenosine
and about 1 mM to about 12.5 mM MnCl.sub.2. The composition may
also contain an amino acid such as e.g., leucine, valine, and
alanine. The method preserves the function of a protein (such as
e.g., an enzyme) during desiccation or when the protein is exposed
to radiation (such as e.g., UV light, alpha radiation, beta
radiation, gamma radiation, X-ray radiation and neutron
radiation).
[0012] Another embodiment of the invention is a method for storing
a protein comprising contacting a protein with a composition
comprising one or more purine nucleosides and one or more
antioxidants.
[0013] Yet another embodiment of the invention is a method of
treating and/or preventing a side effect of radiation exposure in a
subject in need thereof comprising administration of a
pharmaceutically effective amount of a D. radiodurans extract
comprising one or more purine nucleosides and one or more
antioxidants to a subject in need thereof. The method is suitable
for treating radiation exposure from a variety of sources. In one
embodiment, the radiation is UV light, alpha radiation, beta
radiation, gamma radiation, X-ray radiation and neutron radiation.
The one or more purine or pyrimidine nucleoside may be adenosine,
uridine, .beta.-pseudouridine, inosine, and mixtures thereof. The
one or more oxidants may be manganese, MnCl.sub.2, manganous
phosphate and Vitamin E. In one embodiment of the invention, the
antioxidant is manganous phosphate. In another embodiment, the
antioxidant is MnCl.sub.2 with phosphate added separately. The D.
radiodurans extract may also contain an amino acid, preferably
alanine, valine, leucine, or mixtures thereof. In one embodiment,
the method prevents one or more side effects of radiotherapy. The
D. radiodurans extract may contain about 1 mM to about 15 mM of
adenosine and/or uridine. The extract may also contain about 1 mM
to about 12.5 mM of manganese.
[0014] The D. radiodurans extract may be produced by harvesting a
D. radiodurans culture by centrifugation, lying the D. radiodurans
culture to create a D. radiodurans lysate, washing the D.
radiodurans lysate, centrifuging the D. radiodurans lysate for a
time and under conditions sufficient to create a supernatant,
passing the supernatant through a less than 3 kiloDalton filter;
and boiling the supernatant for about 15 to about 45 minutes. The
extract is soluble in butane, resistant to boiling and
cell-free.
BRIEF DESCRIPTION OF THE DRAWINGS
[0015] The foregoing summary, as well as the following detailed
description of the invention, will be better understood when read
in conjunction with the appended figures. For the purpose of
illustrating the invention, shown in the figures are embodiments of
the present invention. It should be understood, however, that the
invention is not limited to the precise arrangements, examples, and
instrumentalities shown.
[0016] FIG. 1 shows that compounds in D. radiodurans ultrafiltrates
protect proteins but compounds ultrafiltrates from in Pseudonomas
putida (PP), Escherichia coli (EC), and Thermus thermophilus (TT)
do not. Protein-free, ultra-filtrated D. radiodurans (DR) cell
extract prevents ionizing radiation (IR)-induced protein oxidation
in vitro, but extracts from the radiation sensitive bacteria
Pseudomonas putida (PP), Escherichia coli (EC), and Thermus
thermophilus (TT) did not. Purified E. coli proteins were incubated
in PP-, EC-, TT-, or DR-ultra-filtrated extract during irradiation,
and subjected to a protein carbonyl assay. Coomassie-stained
polyacrylamide denaturing gel; Carbonyl Western blot, revealing
protein oxidation and protection (no signal).
[0017] FIG. 2 shows that Adenosine and Uridine Prevent
Gamma-Radiation-Induced Protein Breaks and Carbonylation
(Oxidation). Adenosine and uridine prevent ionizing radiation
(IR)-induced protein oxidation in vitro. Purified E. coli proteins
were incubated with the indicated agents. Coomassie-stained
polyacrylamide denaturing gel; Carbonyl Western blot, revealing
protein oxidation (black) and protection (no signal). For example,
when E. coli proteins were irradiated in potassium phosphate buffer
(PPB/25 mM)+15 mM adenosine (Ad), the proteins were highly
protected from oxidation during irradiation compared to potassium
phosphate buffer alone.
[0018] FIG. 3 shows the radioprotective properties for a
composition containing Adenosine and Manganese, i.e. a
radioprotective composition based on D. radiodurans.
Post-irradiation functionality of restriction enzyme BamH1 after
indicated treatment and incubation with 1-DNA. For example, when
BamH1 is irradiated in 25 mM potassium phosphate buffer (PPB)+3 mM
adenosine (Ad)+1 mM MnCl.sub.2, the enzyme remains functional after
exposure to 17,500 Gy, but not when incubated in potassium
phosphate buffer alone, adenosine alone or MnCl.sub.2 alone.
[0019] FIG. 4A-4C show radioprotection by D. radiodurans
protein-free cell extracts of human T-cells compared to
well-established radioprotective compounds. D. radiodurans extract
(4.times. concentrated, 100 .mu.l/ml), Amifostine (200 .mu.g/ml),
or 5-AED (10 mg/ml) were added to human Jurkat T cells 24 hr before
exposure to 8 Gy (0.6 Gy/min). Viability of cells 24 (FIG. 4A), 48
(FIG. 4B), and 72 hours (FIG. 4C) after irradiation was measured by
trypan blue exclusion. *P<0.05 vs. Veh, DRE, and DRE+IR,
determined by Student t-test. CON: non-irradiated, IR: gamma
radiation; VEH: water as vehicle; DRE: D. radiodurans extract; AMF:
Amifostine; 5-AED: 5-androstenediol.
[0020] FIG. 5A-5D show in vivo desiccation-induced oxidative
protein damage. The proteins were isolated from the indicated
strains after 6 days of desiccation. 20-mg samples were subjected
to polyacrylamie denature gel electrophoreses and stained with
Coomassie Blue (FIG. 5A). A duplicate unstained gel was subjected
to assay for carbonyl groups (FIG. 5B). Abbreviations: O=oxidized
protein standards; S=protein-size standards. Deinococcus species
are in bold: R1 (type-strain); 1A1; 1A6; 3B1; 5A4 (surface
isolates) and 7b-1. Non-Deinococcus species: 4A4 Methylobacterium;
4A6, Chelatococcous. So, S. oneidensis. FIG. 5C shows the
corresponding values for intracellular Mn/Fe contractions, 10% IR
survival (D10) and survival following 1, 2, and 3 weeks (w) of
desiccation are tabulated. FIG. 5D shows in vitro protection of
restriction enzyme from drying-induced deactivation by D.
radiodurans protein-free cell extract.
DETAILED DESCRIPTION
General Description
[0021] The inventors have studied the radio-resistance of D.
radiodurans and prepared ultra-purified, protein free-cell extracts
that exhibit radioprotective properties. Thus, the invention is
based in part on the discovery of radioprotective components of D.
radiodurans cell free extract and artificial compositions
containing such components.
[0022] In particular, applicants have shown that D. radiodurans
ultra-purified and protein-free cell extracts are extremely
radioprotective of proteins exposed to gamma-radiation. Adenosine
and uridine are accumulated in D. radiodurans, but these
nucleosides were undetectable in radiation sensitive bacteria. In
vitro, at doses >10,000 Gy, nucleosides were shown to be highly
protective of proteins, preventing ionizing radiation (IR)-induced
protein carbonylation and preserve the function enzymes in the
presence of Mn(II). A radioprotective composition of adenosine,
manganese and phosphate was been developed. Surprisingly, D.
radiodurans extracts have been shown to be potent radioprotectors
for cultured human T-cells with greater potency than other
well-established radioprotective compounds.
[0023] The present invention provides for radioprotective
compositions either synthetic or derived from D. radiodurans and
methods of uses of these compositions to protect proteins and/or
cells from radiation damage. These compositions are useful to
prevent radiation damages in compositions as well as in subjects
such as humans. In particular, this invention provides for
radioprotective compositions that contain one or more purine
nucleoside and one or more antioxidant. The radioprotective
compositions may further contain leucine, alanine, and/or valine.
Leucine is strongly implicated in scavenging hydrogen peroxide in
the presence of Mn(II), and may be components of larger
intracellular complexes that include uridine and adenosine. Strong
in vitro evidence indicates a synergistic effect between adenosine
and manganese. The stoichiometry of adenosine and manganese may be
optimized for an apoptosis assay.
[0024] Applicants have shown that adenosine alone and Mn(II) alone
are radioprotective in vivo for a mammalian cell line.
[0025] Although not being bound by any particular theory, it is
believed that compositions comprising purine nucleosides (e.g.
adenosine) and an antioxidant (e.g. manganese) act as
radioprotectants by shielding a proteins' active site. The purine
nucleoside e.g. adenosine (and optionally with the pyrimidine
uridine) mediates its radioprotective effects upon accumulation
within a cell, which inhibits radiation-induced protein oxidation,
and in the presence of Mn(II) preserves enzyme function. Adenosine
is thought to protect proteins, and therefore scavenge a subset of
ROS.
[0026] Furthermore, without being bound by any particular theory,
it is believed that under aerobic or anaerobic irradiation
conditions, superoxide can build up in cells during irradiation
because superoxide does not readily cross membranes. Although
superoxide does not react with DNA, superoxide will damage and
inactivate enzymes with exposed 2Fe-2S or 4Fe-4S clusters,
releasing Fe(II). The problem with iron in a cell, when it is
unbound and "free", is that it causes Fenton reactions in the
presence of hydrogen peroxide, generating hydroxyl radicals.
Therefore, conditions which liberate bound Fe(II) are extremely
dangerous, not only because of the generation of hydroxyl radicals,
but because the loss of Fe from Fe-dependent enzymes leads to the
failure of the biochemical pathways within which they operate. The
methods of the instant application optimally protect against these
dangerous conditions.
[0027] Unless defined otherwise, all technical and scientific terms
used herein have the same meaning as commonly understood by one of
ordinary skill in the art to which this invention belongs. Although
any methods and materials similar or equivalent to those described
herein can be used in the practice or testing of the present
invention, the preferred methods, and materials are described.
[0028] As used herein, "a" or "an" means at least one, unless
clearly indicated otherwise. The term "about," unless otherwise
indicated, refers to a value that is no more than 10% above or
below the value being modified by the term. For example, the term
"about 5% (w/w)" means a range of from 4.5% (w/w) to 5.5%
(w/w).
Methods of Preserving Protein Function
[0029] This invention provides for methods of preserving protein
function by contacting a protein with a composition comprising one
or more purine nucleosides and one or more antioxidants. One
embodiment of the invention is a method preserving protein function
when the protein is exposed to the extreme conditions of radiation
such as e.g. gamma radiation. In another embodiment of the
invention, the method preserves protein function during
desiccation. The methods of preserving protein function provide
radioprotection when the protein is exposed to high dose of
radiation such as doses in excess of 10 kGy, e.g., 17.5 kGy.
[0030] In another embodiment, the invention provides for methods of
protecting protein function in a cell culture comprising one or
more purine nucleosides and one or more antioxidants. The cell
culture may be prokaryotic or eukaryotic. In one embodiment, the
cell culture is mammalian.
[0031] Any purine or pyrimidine nucleoside may be used in the
composition. Suitable purine or pyrimidine nucleosides include, but
are not limited to, adenosine, uridine, .beta.-pseudouridine,
inosine, and mixtures thereof. Preferably the purine or pyrimidine
nucleoside is adenosine or uridine, repspectively. In one
embodiment, the composition contains adenosine. In other embodiment
of the invention, the composition contains the pyrimidine uridine
and/or .beta.-pseudouridine. The amount of purine or pyrimidine
nucleoside in the composition varies on its use. Those of skill in
the art will be able to determine the suitable amount. In some
embodiments of the invention, the amount of purine or pyrimidine
nucleoside ranges from about 0.01 mM to about 15 mM, from about 0.1
mM to about 1 mM, from about 1 mM to about 10 mM, from about 1 mM
about 15 mM. In one embodiment, the concentration of one or more
purine and/or pyrimidine nucleosides comprises about 1 mM to about
15 mM of adenosine and/or uridine.
[0032] A variety of antioxidants maybe used in the composition.
Suitable antioxidants include manganese, vitamin E and manganous
phosphate. In one embodiment of the invention, the antioxidant is
manganese. In another embodiment, the antioxidant is MnCl.sub.2. In
yet another embodiment, the antioxidant is vitamin E. The amount of
antioxidant in the composition varies on its use. Those of skill in
the art will be able to determine the suitable amount. In one
embodiment, the composition contains about 0.01 mM to about 15 mM
of the antioxidant. In another embodiment, the composition contains
about 0.01 mM to about 12.5 mM.
[0033] In one embodiment of the invention, a critical antioxidant
is manganous phosphate which may be provided at near-millimolar
concentrations. In another embodiment, the antioxidant is
MnCl.sub.2, with phosphate added separately. The amount of
antioxidant in the composition varies on its use. Those of skill in
the art will be able to determine the suitable amount. In one
embodiment, the composition contains about 0.01 mM to about 15 mM
of the manganous (Mn(II)) ions and 1 mM to about 25 mM phosphate
buffer.
[0034] The compositions may further contain one or more amino acids
that exhibit cytoprotective properties. In one embodiment of the
invention, composition further contains at least one or more amino
acid selected from the group consisting of leucine, valine, and
alanine. In another embodiment, the amino acid is leucine. In an
alternate embodiment, the amino acid is glycine.
[0035] In one embodiment, the composition comprises adenosine,
uridine, leucine, adenine, and manganese. In an alternate
embodiment, the composition comprises about 1 to about 15 mM
adenosine and about 1 to about 12.5 mM MnCl.sub.2. In another
embodiment, the composition comprises a D. radiodurans extract
containing one or more purine nucleosides and one or more
antioxidants.
[0036] Any protein function may be preserved by use of the methods
of this invention. In a preferred embodiment of the invention, the
protein is an enzyme. The methods of the instant disclosure are
particularly useful in preventing protein oxidation associated with
ultraviolet radiation and aging. Furthermore, the methods also
preserve protein functionality during desiccation and thus help
increase the shelf life of desiccated blood products and
enzyme-based drugs, which are stored dry.
[0037] The methods of the invention optimally preserve protein
function (such as e.g., enzymatic activity) during exposure to
radiation. One embodiment of the invention is a method of
preservation comprising contacting a protein (such as e.g., an
enzyme) with a composition comprising one or more purine
nucleosides and one or more antioxidants.
[0038] Another embodiment of the invention is a method of
increasing the durability and longevity of microbial and
enzyme-driven fuel cells comprising contacting the components of
the fuel cell with a composition comprising one or more purine
nucleosides and one or more antioxidants.
[0039] This method may be suitable to preserve the function of many
proteins including but not limited to proteins with Fe--S complexes
(such as metabolic enzymes) and enzymatic repair functions that are
dependent on redox-active (4Fe-4S) clusters. Exemplary proteins
include protein groups associated with the production of reactive
oxygen species (ROS), transport protein precursors which might
reduce biosynthetic demands and suppress the production of ROS,
proteins that defend against ROS, proteins that participate in
repair of damaged molecules (non-DNA) and redox regulation as well
as Mn and Fe-dependent systems. Other exemplary proteins are listed
in Ghosal et al. (2005), FEMS Microbiology Reviews 29: 361-375, the
disclosure of which is herein incorporated in its entirety.
Methods of Treating or Preventing the Effects of Radiation
Exposure
[0040] The invention also provides for methods of treating or
preventing the effects of radiation exposure. The methods comprise
treating or preventing the effects of radiation exposure with a
therapeutic agent comprising one or more purine nucleosides and one
or more antioxidants.
[0041] In one embodiment of the invention, the radiation exposure
is due to UV exposure. In another embodiment of the invention, the
radiation exposure is due to ionizing radiation. In another
embodiment of the invention, the radiation exposure is chronic.
[0042] As used herein, the term "therapeutic agent" shall encompass
compositions comprising one or more purine nucleosides and one or
more antioxidants as well as formulations containing other
pharmaceutically acceptable components such as e.g.
pharmaceutically acceptable carriers.
[0043] As used herein, the term "radiation exposure" shall mean
exposure to any radiation in a dose and for a period sufficient to
cause damage. Radiation exposure includes but it is not limited to
exposure to UV light, alpha radiation, beta radiation, gamma
radiation, X-ray radiation and neutron radiation.
[0044] In one embodiment, the invention provides for methods of
treating or preventing the side effects of radiotherapy. As used
herein, the term "radiotherapy" shall refer to the use of certain
types of energy (such as e.g., ionizing radiation) to kill cancer
cells and shrink tumors. The term "radiotherapy" includes all types
of radiotherapy including but not limited to external radiation
therapy (such as e.g., intraoperative radiotherapy and prophylactic
cranial irradiation (PC)), internal radiation therapy (such as
e.g., interstitial radiation therapy, intracavitary or intraluminal
radiation therapy), systemic radiation therapy, stereotactic (or
stereotaxic) radiosurgery, three-dimensional (3-D) conformal
radiation therapy, intensity-modulated radiation therapy (IMRT).
Furthermore, the term "radiotherapy" also encompasses radiotherapy
using a variety of sources of radiation including but not limited
to X-rays, gamma rays, particle beams, proton beam therapy, and
high-energy photon radiation. Radiotherapy is used to treat a
variety of cancers including solid tumors (such as e.g., cancers of
the brain, breast, cervix, larynx, lung, pancreas, prostate, skin,
spine, stomach, uterus, or soft tissue sarcomas). Radiotherapy is
also used to treat leukemia and lymphoma (i.e., cancers of the
blood-forming cells and lymphatic system, respectively) as well as
cancers of the skin, cervix, and thyroids.
[0045] As used herein, the term "side effects of radiotherapy"
shall be refer to any side effect experienced by a subject
undergoing radiotherapy. Such side effects include but are not
limited to tiredness and skin reactions, anemia, increased risk of
bruising or bleeding, decreased fertility, dry mouth, loss of
appetite and weight, hair loss etc.
[0046] A "subject in need of treatment" is an animal with a
bacterial infection that is potentially life-threatening or that
impairs health or shortens the lifespan of the animal. The animal
can be a fish, bird, or mammal. Exemplary mammals include humans,
domesticated animals (e.g., cows, horses, sheep, pigs, dogs, and
cats), and exhibition animals, e.g., in a zoo. In a preferred
embodiment, the subject is human.
[0047] The terms "treating", "treatment," and "therapy" as used
herein refer to curative therapy, prophylactic therapy, and
preventative therapy.
[0048] As used herein, unless stated otherwise, the term
composition is meant to encompass, and not limited to,
pharmaceutical compositions and nutraceutical compositions
containing one or more purine nucleosides and one or more
antioxidants. The composition may also contain one or more
"excipients" that are "inactive ingredients" or "compounds" devoid
of pharmacological activity or other direct effect in the
diagnosis, cure, mitigation, treatment, or prevention of disease or
to affect the structure or any function of the human body.
[0049] A "pharmaceutically acceptable" component is one that is
suitable for use with humans, animals, and/or plants without undue
adverse side effects (such as e.g., toxicity, irritation, and
allergic response) commensurate with a reasonable benefit/risk
ratio.
[0050] The therapeutic agent may contain any purine or pyrimidine
nucleoside. Suitable purine or pyrimidine nucleosides include but
are not limited to adenosine, uridine, .beta.-pseudouridine,
inosine, and mixtures thereof. Preferably the purine or pyrimidine
nucleoside is adenosine or uridine. In one embodiment, the
therapeutic agent contains adenosine. In other embodiment of the
invention, the therapeutic agent contains the pyrimidine
uridine.
[0051] The therapeutic agent may contain a variety of suitable
antioxidants. Suitable antioxidants include but are not limited to
manganese, vitamin E, and manganous phosphate. In one embodiment of
the invention, the antioxidant is manganese. In another embodiment,
the antioxidant is MnCl.sub.2. In yet another embodiment, the
antioxidant is vitamin E.
[0052] In one embodiment of the invention, a critical antioxidant
is manganous phosphate, which may be provided at near-millimolar
concentrations. In another embodiment, the antioxidant is
MnCl.sub.2, with phosphate added separately. The amount of
antioxidant in the composition varies on its use. Those of skill in
the art will be able to determine the suitable amount. In one
embodiment, the composition contains about 0.01 mM to about 15 mM
of the manganous (Mn(II)) ions and 1 mM to about 25 mM phosphate
buffer.
[0053] The amount of purine or pyrimidine nucleoside and
antioxidant in the therapeutic agent varies. Those of skill in the
art will be able to determine the suitable amount depending on a
variety of factor such as the subject, the duration of the
radiation exposure, the amount of the radiation exposure etc. In
some embodiments of the invention, the amount of purine and/or
pyrimidine nucleoside ranges from about 0.01 mM to about 15 mM,
from about 0.1 mM to about 1 mM, from about 1 mM to about 10 mM,
from about 1 mM about 15 mM. In one embodiment, the concentration
of one or more purine and/or pyrimidine nucleosides comprises about
1 mM to about 15 mM of adenosine and/or uridine. In another
embodiment, the amount of antioxidant ranges from about 0.01 mM to
about 15 mM. In another embodiment, the therapeutic agent contains
about 0.01 mM to about 12.5 mM.
[0054] The therapeutic agent may further contain one or more amino
acids that exhibit cytoprotective properties. In one embodiment of
the invention, therapeutic agent further contains at least one or
more amino acid selected from the group consisting of leucine,
valine, and alanine. In another embodiment, the amino acid is
leucine. In another embodiment, the amino acid is glycine.
[0055] In one embodiment, the therapeutic agent comprises
adenosine, uridine, leucine, adenine, and manganese. In an
alternate embodiment, the therapeutic agent comprises about 1 mM to
about 15 mM adenosine and about 1 mM to about 12.5 mM MnCl.sub.2.
In another embodiment, the therapeutic agent comprises a D.
radiodurans extract containing one or more purine nucleosides and
one or more antioxidants.
[0056] In yet another embodiment of the invention, the therapeutic
agent is a composition suitable for human use comprising one or
more purine or pyrimidine nucleoside (such as e.g., adenosine,
uridine, .beta.-pseudouridine, inosine, and mixtures thereof), one
or more antioxidant (such as e.g., manganese, vitamin E) and
optionally one or more amino acid selected from the group
consisting of leucine, valine, and alanine. In one embodiment, the
composition suitable for human use comprises adenosine and
manganese.
[0057] In an alternate embodiment of the invention, the therapeutic
agent is a D. radiodurans extract containing one or more purine
nucleosides and one or more antioxidants.
[0058] The methods for treating or preventing the effects of
radiation exposure comprise administration of a therapeutic agent
comprising one or more purine nucleosides and one or more
antioxidants to a subject in need thereof.
[0059] One embodiment is a method of preventing a side effect of
radiotherapy, comprising administration of a D. radiodurans extract
comprising one or more purine nucleosides and one or more
antioxidants to a subject in need thereof.
[0060] Another embodiment of the invention is a method of
preventing a side effect of radiotherapy comprising administration
of a composition comprising one or more purine nucleosides, an
antioxidant and optionally an amino acid selected from the group
consisting of alanine, valine and leucine to a subject in need
thereof. Preferably the one or more purine and/or pyrimidine
nucleoside is adenosine and/or uridine, which may be present in
amounts from about 1 mM to about 15 mM of adenosine and/or uridine.
The one or more purine or pyrimidine nucleosides may also selected
from the group consisting of adenosine, uridine,
.beta.-pseudouridine, inosine, and mixtures thereof. The
antioxidant may be manganese (e.g. of about 1 mM to about 12.5 mM).
In one embodiment, the antioxidant is MnCl.sub.2. In another
embodiment, the antioxidant is vitamin E. In another embodiment,
the composition comprises adenosine, uridine, leucine, adenine, and
manganese.
[0061] The methods of the instant application are particularly
advantageous. Compared to well-established radioprotectors (such
e.g. amifostine), compositions comprising one or more purine and/or
pyrimidine nucleosides and one or more antioxidants (e.g.,
adenosine, uridine and Mn) are relatively non-toxic.
[0062] The methods of the invention are particularly suitable for
pre- and post-exposure treatments of military personnel and
civilians accidentally or deliberately exposed to ionizing
radiation.
[0063] The methods may also used prophylactically for individuals
exposed to significant chronic levels of radiation such as in
nuclear power plants, during long-duration space flight, or on the
international space station.
[0064] A "safe and effective amount" refers to a quantity of a
component that is sufficient to yield a desired therapeutic
response without undue adverse side effects (such as toxicity,
irritation, or allergic response) commensurate with a reasonable
benefit/risk ratio when used in the manner of this invention. By
"therapeutically effective amount" is meant an amount of a
component effective to yield a desired therapeutic response, e.g.,
an amount effective to slow the rate of bacterial cell division, or
to cause cessation of bacterial cell division, or to cause death or
decrease rate of population growth of the bacteria. The specific
safe and effective amount or therapeutically effective amount will
vary with such factors as the particular condition being treated,
the physical condition of the subject, the type of subject being
treated, the duration of the treatment, the nature of concurrent
therapy (if any), and the specific formulations employed and the
structure of the compounds or its derivatives.
[0065] Means of application include, but are not limited to direct,
indirect, carrier and special means or any combination of means.
Direct application of the phage may be by nasal sprays, nasal
drops, nasal ointments, nasal washes, nasal injections, nasal
packings, bronchial sprays and inhalers, or indirectly through use
of throat lozenges, or through use of mouthwashes or gargles, or
through the use of ointments applied to the nasal nares, the bridge
of the nose, or the face or any combination of these and similar
methods of application. The forms in which the phage may be
administered include but are not limited to lozenges, troches,
candies, injectants, chewing gums, tablets, powders, sprays,
liquids, ointments, and aerosols.
[0066] The therapeutic agent may also be placed in a nasal spray,
wherein the nasal spray is the carrier. The nasal spray can be a
long acting or timed release spray, and can be manufactured by
means well known in the art. An inhalant may also be used, so that
the therapeutic agent may reach further down into the bronchial
tract, including into the lungs.
[0067] The therapeutic agent may be added to these substances in a
liquid form or in a lyophilized state, whereupon it will be
solubilized when it meets body fluids such as saliva. The enzyme
may also be in a micelle or liposome.
[0068] While these methods may be used in any mammalian species
such as farm animals including, but not limited to, horses, sheep,
pigs, chicken, and cows, the preferred use of compositions is for a
human.
[0069] The effective dosage rates or amounts of the compositions
will depend in part on whether the composition will be used
therapeutically or prophylactically, the duration of exposure of
the recipient to radiation, the type of radiation, the size, and
weight of the individual, etc. The duration for use of the
composition also depends on whether the use is for prophylactic
purposes, wherein the use may be hourly, daily or weekly, for a
short time period, or whether the use will be for therapeutic
purposes wherein a more intensive regimen of the use of the
composition may be needed, such that usage may last for hours, days
or weeks, and/or on a daily basis, or at timed intervals during the
day. Any dosage form employed should provide for a minimum number
of units for a minimum amount of time. The concentration of the
active units of phage believed to provide for an effective amount
or dosage of phage may be in the range of about 100 units/ml to
about 100,000 units/ml of fluid in the wet or damp environment of
the nasal and oral passages, and possibly in the range of about 100
units/ml to about 10,000 units/ml. More specifically, time exposure
to the radiation may influence the desired concentration of active
radioprotective composition units per ml. It should be noted that
carriers that are classified as "long" or "slow" release carriers
(such as, for example, certain nasal sprays or lozenges) could
possess or provide a lower concentration of the composition per ml,
but over a longer period of time, whereas a "short" or "fast"
release carrier (such as, for example, a gargle) could possess or
provide a high concentration of composition per ml, but over a
shorter period of time. It will furthermore be appreciated that a
therapeutically effective amount of a particular composition can be
determined by those of ordinary skill in the art with due
consideration of the factors pertinent to the subject.
[0070] Selection of the preferred effective dose can be determined
(e.g., via clinical trials) by a skilled artisan based upon the
consideration of several factors which will be known to one of
ordinary skill in the art. Such factors include the disease to be
treated or prevented, the symptoms involved, the patient's body
mass, the patient's immune status and other factors known by the
skilled artisan to reflect the accuracy of administered
pharmaceutical compositions.
[0071] The precise dose to be employed in the formulation will also
depend on the route of administration and should be decided
according to the judgment of the practitioner and each patient's
circumstances. Effective doses may be extrapolated from
dose-response curves derived from in vitro or animal model test
systems.
[0072] For the prophylactic and therapeutic treatment and/or
prevention of the effects of radiation exposure, the compositions
comprising purine nucleosides and antioxidants may also be applied
by direct, indirect, carriers and special means or any combination
of means. Direct application of the phage may be by nasal sprays,
nasal drops, nasal ointments, nasal washes, nasal injections, nasal
packings, bronchial sprays and inhalers, or indirectly through use
of throat lozenges, or through use of mouthwashes or gargles, or
through the use of ointments applied to the nasal nares, the bridge
of the nose, or the face or any combination of these and similar
methods of application. The forms in which the phage may be
administered include but are not limited to lozenges, troches,
candies, injectants, chewing gums, tablets, powders, sprays,
liquids, ointments, and aerosols. For the therapeutic treatment of
anthrax, the bronchial sprays and aerosols are most beneficial, as
these carriers, or means of distributing the composition, allow the
phage to reach the bronchial tubes and the lungs.
[0073] The compositions of the present invention can be
administered via parenteral, subcutaneous, intravenous,
intramuscular, intraperitoneal, transdermal, or buccal routes. For
example, an agent may be administered locally to a site of injury
via microinfusion. Alternatively, or concurrently, administration
may be by the oral route. The dosage administered will be dependent
upon the age, health, and weight of the recipient, kind of
concurrent treatment, if any, frequency of treatment, and the
nature of the effect desired.
[0074] In one embodiment of the invention, the method comprises
administration of the therapeutic agent in a pharmaceutically
acceptable carrier. Suitable carriers and their formulations are
described in Remington's Pharmaceutical Sciences, 2005, Mack
Publishing Co. Typically, an appropriate amount of a
pharmaceutically acceptable salt is used in the formulation to
render the formulation isotonic. Examples of the pharmaceutically
acceptable carrier include liquids such as saline, Ringer's
solution, and dextrose solution. The pH of the solution is
preferably from about 5 to about 8, and more preferably from about
7 to about 7.5. The formulation may also comprise a lyophilized
powder. Further carriers include sustained release preparations
such as semi-permeable matrices of solid hydrophobic polymers,
which matrices are in the form of shaped articles, e.g., films,
liposomes or microparticles. It will be apparent to those persons
skilled in the art that certain carriers may be more preferable
depending upon, for instance, the route of administration and
concentration of proinflammatory cytokine inhibitor being
administered.
[0075] The methods optimally provide therapeutics against numerous
redox-related forms of cell injury mediated by protein damage, and
facilitate wound healing.
Methods of Preparing D. radiodurans Extracts
[0076] One embodiment of the invention is a method of preparing D.
radiodurans cell-free extracts that exhibit radio-protective
properties. In one embodiment, the methods has the steps of
harvesting a D. radiodurans by e.g., centrifugation, lysing the D.
radiodurans culture to create a lysate, washing the D. radiodurans
lysate followed by centrifuging the lysate for a time and under
conditions sufficient to create a supernatant. After
centrifugation, the supernatant is passed through a microfilter,
preferably a 3 kiloDalton Microfilter, and boiled for a period for
a suitable amount of time. In one embodiment, the supernatant is
boiled for about 15 to about 45 minutes after filtration. The
resulting D. radiodurans extract contains one or more purine
nucleosides and one or more antioxidants, is soluble in butanol,
resistant to boiling, and cell-free.
[0077] In one embodiment, the extract contains adenosine and
manganese. In another embodiment, the extract contains adenosine
and/or uridine manganese. The cell extracts may also further
contain leucine, alanine, and/or valine. In one embodiment, the D.
radiodurans extract contains at least adenosine, uridine, leucine,
adenine, and manganese.
[0078] Without further description, it is believed that one of
ordinary skill in the art can, using the preceding description and
the following illustrative examples, make and utilize the present
invention and practice the claimed methods. The following working
examples therefore, specifically point out the preferred
embodiments of the present invention, and are not to be construed
as limiting in any way the remainder of the disclosure.
EXAMPLES
Example 1
[0079] Preparation of Protein-Free Extract from D. radiodurans.
[0080] D. radiodurans (ATTC BAA-816) was grown to OD600 0.9 in TGY,
harvested by centrifugation, and lysed by French pressure
treatment. The cells were washed and then lysed in
double-distilled, de-ionized sterile water (dH.sub.2O). Prior to
lysis, cell density was adjusted with dH.sub.2O to yield lysates
representing approximately 50% intracellular concentration. Crude
cell extracts were centrifuged for 20 hours at 175,000.times.g. The
supernatant was passed through a <3 kiloDalton Microcon
centrifugal filter (Millipore, USA) and boiled for 30 min. The
Coomassie (Bradford) protein assay was used to confirm the virtual
absence of proteins in the ultra-purified extracts, which were
aliquoted and stored at -80.degree. C.
Example 2
[0081] Analysis of protein-free extract from D. radiodurans. The D.
radiodurans extracts were analyzed using TOF MS and chromatography.
Using these techniques, the extracts were found to contain a
variety of compounds including but not limited to leucine, adenine,
uridine, and adenosine. Previous analysis showed that these
extracts also contain manganese. The amino acids leucine, alanine,
and valine are very elevated in D. radiodurans and D. geothermalis
compared to radiation sensitive bacteria (data not shown).
Example 3
[0082] Radioprotective Effects in Mammalian Cells.
[0083] Apoptosis of Human Fetal Osteoblastic 1.19 cell line from
ATCC (hFOB) was determined by death and apoptotic markers (Annexin
V and propidium iodide PI) using a flow cytometry assay. In brief,
hFOB cells were cultured in DMEM-F12 with 10% fetal bovine serum,
2.5 mM L-glutamine and 1% antibiotic to full confluency followed by
treatment for experimental groups with adenosine (10 mM) or
MnCl.sub.2 (0.25 mM) or adenosine and MnCl.sub.2 for 6 days period
starting 3 h before IR. Apoptotic cell death was measured by flow
cytometry with Annexin V and PI staining 6 days after IR. hFOB
cells also were plated (1.times.103/well, 6-well plate) for
clonogenic survival assay after IR. Colonies were counted 10 days
later. The results of the assay are shown below in Table 1.
[0084] For the assays, adenosine +/-0.25 mM Mn(II) was added 3
hours prior to irradiation. Cells were assayed 6 days after
irradiation by flow cytometry. Annexin-V conjugates allow for the
identification of cell surface changes that occur early during the
apoptotic process using flow cytometry. Early in the apoptotic
process, phosphatidylserine becomes exposed on the cell surface.
Propidium Iodide (PI) in un-fixed cells discriminates between
apoptosis and necrosis on the basis of dye exclusion. While
necrotic cells lose membrane integrity early on in their death
throws, apoptotic cells may have compromised membranes.
TABLE-US-00001 TABLE 1 exp-1 apoptosis assays: hFOB cells 6 days
after IR Adenosine DMEM Adenosine Mn & Mn Radiation Dosage 0 Gy
8 Gy 0 Gy 8 Gy 0 Gy 8 Gy 0 Gy 8 Gy Annexin-V + 1% 7% 1% 2% 0% 2% 1%
2% PI PI 3% 11% 13% 10% 14% 7% 8% 8% Annexin V+ 10% 26% 2% 3% 0%
21% 3% 8% Live Cells 86% 56% 85% 85% 86% 70% 89% 82%
[0085] While the invention has been described and illustrated
herein by references to various specific materials, procedures and
examples, it is understood that the invention is not restricted to
the particular combinations of material and procedures selected for
that purpose. Numerous variations of such details can be implied as
will be appreciated by those skilled in the art. It is intended
that the specification and examples be considered as exemplary,
only, with the true scope and spirit of the invention being
indicated by the following claims. All references, patents, and
patent applications referred to in this application are herein
incorporated by reference in their entirety.
* * * * *